Screener / CNS Disease Treatments / Supernus Pharmaceuticals
SUPN · NASDAQ
Supernus Pharmaceuticals
Compliant
Under AAOIFI Standard 21, Supernus Pharmaceuticals is compliant. Its core business is permissible and its interest-bearing debt is below 30% of market cap.
TickerSUPN
ExchangeNASDAQ
SectorCNS Disease Treatments
Full ratios for Supernus Pharmaceuticals (impure revenue, debt and interest-bearing deposits under all four standards) are being added. Until then this page shows the screening verdict only. See the methodology for how each test works. Purindex publishes this screening to help people understand what they own. It does not recommend buying, selling or holding Supernus Pharmaceuticals or any other security.